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Abstract
Background: Mutations in SPG4 cause the most common form of autosomal dominant hereditary
spastic paraplegia, a neurodegenerative disease characterized by weakness and spasticity of the
lower limbs due to degeneration of the corticospinal tract. SPG4 encodes spastin, a microtubule-
severing ATPase belonging to the AAA family. Two isoforms of spastin, 68 and 60 kDa, respectively,
are variably abundant in tissues, show different subcellular localizations and interact with distinct
molecules. The isoforms arise through alternative initiation of translation from two AUG codons
in exon 1; however, it is unclear how regulation of their expression may be achieved.
Results: We present data that rule out the hypothesis that a cap-independent mechanism may be
involved in the translation of the 60-kDa spastin isoform. Instead, we provide evidence for a
complex transcriptional regulation of SPG4 that involves both a TATA-less ubiquitous promoter
and a cryptic promoter in exon 1. The cryptic promoter covers the 5'-UTR and overlaps with the
coding region of the gene. By using promoter-less constructs in various experimental settings, we
found that the cryptic promoter is active in HeLa, HEK293 and motoneuronal NSC34 cells but not
in SH-SY-5Y neuroblastoma cells. We showed that the cryptic promoter directs the synthesis of a
SPG4  transcript that contains a shorter 5'-UTR and translates the 60-kDa spastin isoform
selectively. Two polymorphisms (S44L and P45Q), leading to an early onset severe form of
hereditary spastic paraplegia when present in heterozygosity with a mutant allele, fall a few
nucleotides downstream of the novel transcriptional start site, opening up the possibility that they
may exert their modifier effect at the transcriptional level. We provide evidence that at least one
of them decreases the activity of the cryptic promoter in luciferase assays.
Conclusion: We identified a cryptic promoter in exon 1 of the SPG4 gene that selectively drives
the expression of the 60-kDa spastin isoform in a tissue-regulated manner. These data may have
implications for the understanding of the biology of spastin and the pathogenic basis of hereditary
spastic paraplegia.
Background
Hereditary spastic paraplegia (HSP) is a genetically heter-
ogeneous disorder characterized by progressive weakness
and spasticity of the lower limbs owing to retrograde
degeneration of the corticospinal axons [1]. SPG4, the
gene most commonly involved in autosomal dominant
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HSP, encodes spastin, an ATPase belonging to the AAA
family [2]. Spastin acts as a microtubule-severing protein,
suggesting that axonal degeneration in HSP may depend
on defective regulation of cytoskeleton dynamics in long
axonal tracts [3-5]. The identification of several spastin
molecular interactors involved in cell trafficking led to the
proposal that the microtubule-severing activity of spastin
may be coupled to specific processes and therefore, occur
in a regulated manner [6].
Spastin has a complex subcellular localization. It is
enriched in the centrosome in interphase and during
mitosis, similarly to p60 katanin, another microtubule-
severing protein [7,8]. Low levels of spastin are present in
the nucleus of proliferating cells, while neurons show a
prevalent cytoplasmic localization [7,9,10]. We previ-
ously found that one mechanism to regulate targeting of
spastin to specific cell compartments is the alternative ini-
tiation of translation from two AUGs present in exon 1 of
the  SPG4  gene [11]. Both spastin isoforms contain a
nuclear localization signal, however, the long 68-kDa
spastin isoform also bears a nuclear export signal and is
efficiently exported to the cytoplasm in an exportin-
dependent fashion. Conversely, the shorter 60-kDa spas-
tin isoform localizes to both the nucleus and cytoplasm
upon over-expression in eukaryotic cells.
Although both spastin isoforms efficiently sever microtu-
bules [4,5], they display several functional differences.
First, the shorter isoform is the most abundant in all tis-
sues examined, while the longer form is efficiently detect-
able only in brain and spinal cord [11,12]. Second, two
proteins, atlastin and NA14, have been shown to interact
specifically to the N-terminal region of spastin present in
the long isoform but absent in the short isoform
[7,13,14]. Since atlastin is in turn implicated in HSP, this
observation may be of direct relevance to the pathogenesis
of the disease. Third, two polymorphisms (S44L and
P45Q) acting as phenotype modifiers have been identi-
fied in the long-isoform-specific region. Patients carrying
a mutated allele of spastin and one of these two polymor-
phisms on the other allele are affected by a severe disease
with an early age of onset [15-17]. Furthermore, a family
has been described in which one patient with a late onset
mild spastic paraplegia was homozygous for the S44L pol-
ymorphism [18].
In vertebrates, initiator codons are recognized most effi-
ciently within the context GCCRCCaugG, with the purine
(R) in position -3 and the G in position +4 making the
strongest contributions [19]. The main SPG4 open read-
ing frame (ORF) starts with an AUG that resides in a con-
text that deviates significantly from the consensus motif
(TGAaugA). Moreover, an upstream ORF (uORF) overlaps
with the main SPG4 ORF and contains an AUG in a good
Kozak's consensus sequence (GTTaugG). It is expected
that this uORF would drastically inhibit translation from
the first SPG4 AUG, while allowing re-initiation at the sec-
ond AUG that has a G in position +4 and is located at a
sufficient distance from the stop codon of the uORF (Fig-
ure 1). uORFs have been recognized in genes with regula-
tory function and may offer a mechanism to restrict
expression of a toxic product [19,20]. In some cases, lim-
ited access to the main ORF might be achieved by leaky
scanning. In summary, the presence of a uORF that over-
laps with the main SPG4 ORF, as well as the sequence con-
text surrounding the first two AUGs in the main ORF, may
explain why translation of the long spastin isoform is
strongly unfavored in vivo. Consistent with this model,
expression of an SPG4 cDNA containing the 5'-UTR abun-
dantly produces the shorter protein isoform and only a
limited amount of the long 68-kDa isoform [11]. Moreo-
ver, in vitro transcription-translation assays using a cDNA
construct that starts from the first AUG supported transla-
tion of both spastin isoforms, likely reflecting leaky scan-
ning from the first AUG [11].
Schematic representation of the SPG4 first exon Figure 1
Schematic representation of the SPG4 first exon. Translation of spastin initiates from two in-frame start codons (+1 and 
+259). A uORF overlaps with the first in-frame AUG and may serve to divert some ribosomes to the downstream start site.BMC Biology 2008, 6:31 http://www.biomedcentral.com/1741-7007/6/31
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Although the scanning mechanism for initiation of trans-
lation can satisfactorily explain our previous data, there
might still be the possibility that translation of the short
abundant 60-kDa spastin isoform occurs via direct entry
of the ribosomes at the downstream AUG codon. Albeit
this mechanism is well documented for certain viral
genes, it is still quite controversial as to whether it occurs
in mammalian genes [21,22].
While testing for the presence of an internal ribosome
entry site (IRES) in the SPG4 mRNA, we found evidence
for a cryptic promoter in exon 1, responsible for the pro-
duction of a shorter mRNA specific for the 60-kDa spastin
isoform. This promoter shows some degree of tissue-spe-
cificity, providing a way to regulate the production of the
different spastin isoforms.
Results
Translation of the 60-kDa spastin isoform does not depend 
on an IRES
Translation of the 60-kDa spastin isoform from the AUG
in position 259–261 may depend on the migration of the
translational machinery until it meets this AUG codon
that lies in a better Kozak's sequence context than the first
AUG (Figure 1). However, the program UTRScan predicts
a secondary RNA structure compatible with the presence
of an IRES, immediately upstream of the second AUG,
suggesting that the short spastin isoform could be synthe-
sized through a cap-independent mechanism. To test this
possibility, we cloned the SPG4 cDNA sequence between
the first and second ATG into a widely used dicistronic
vector, pRF (construct pRF +4/+258). This vector contains
the SV40 promoter directing the expression of a dicis-
tronic RNA encoding the Renilla luciferase as the first cis-
tron and the firefly luciferase as the second. This plasmid
was transfected in HeLa and SH-SY-5Y neuroblastoma cell
lines and the Renilla and firefly luciferase activities were
measured. The construct pRF +4/+258 displayed a high
firefly activity in HeLa cells compared with the control
empty vector (Figure 2a), consistent with the possibility
that the region between the two AUGs in the first exon of
SPG4 might contain a functional IRES. This construct was
less active in SH-SY-5Y cells.
Although the dicistronic test has been considered the gold
standard for testing the existence of functional IRES ele-
ments, a major drawback of this approach is that it cannot
distinguish between IRES activity and the presence of a
cryptic promoter [23]. To exclude this possibility, we
cloned the same SPG4 sequence into a promoter-less pRF
vector (pRFΔP), in which the SV40 promoter has been
removed (Figure 2b). Both Renilla and firefly luciferase
activities were almost undetectable when the empty
pRFΔP vector was transfected, whereas a dramatic increase
of firefly activity was observed for the pRFΔP +4/+258
construct in HeLa cells, strongly suggesting the presence of
a promoter activity in the first exon of SPG4 (Figure 2b).
Again, the fold of activation was lower in SH-SY-5Y cells
(Figure 2b).
The presence of a strong promoter in the region under
analysis could mask the presence of the IRES, hampering
the detection of its functionality. To circumvent this prob-
lem, an effective method is direct transfection of the dicis-
tronic RNAs [23]. To this end, in vitro-transcribed capped
dicistronic mRNAs were transfected into HeLa cells and
the activities of both Renilla and firefly luciferases were
measured. The firefly activities of both the empty vector
and the pRF +4/+258 were barely detectable, while the
Renilla  luciferase activities were comparable, indicating
that the first exon of SPG4 does not contain an IRES ele-
ment (Figure 2c).
A minimal ubiquitous SPG4 promoter
The finding of promoter activity in the region between the
two ATGs prompted us to study the regulatory sequences
of the SPG4 gene. Bioinformatic analysis of the genomic
region upstream of the transcriptional start site (defined
as in the reference sequence AB029006) does not identify
any TATA box, but detects several CG boxes and a CAAT
box in position -597. Furthermore, sequence comparison
between the human and mouse SPG4 genomic sequence
shows a high degree of sequence conservation in the 5'-
UTR of SPG4  and in a region of 400 base pairs (bp)
upstream of the putative initiation of transcription, sug-
gesting that this region may contain important regulatory
elements (Figure 3a).
To define the minimal genomic region that confers basic
expression of the SPG4 gene, we tested the ability of dif-
ferent fragments of the genomic region upstream of the
first ATG of the SPG4 gene to drive the expression of the
luciferase gene in transiently transfected HeLa, HEK293
and SH-SY-5Y cells (Figure 3b). The activities of these pro-
moters were measured by a luciferase assay and consid-
ered as fold of induction in respect to the activity of the
empty vector. We did not find any cell-specific difference
in the activities of the different fragments in the three cell
lines (Figure 3c). The construct that showed higher pro-
moter activity was S -621/-1, which contained the highly
conserved, 400 bp-genomic region and the 5'-UTR. Inclu-
sion of an additional 669 bp upstream of this region led
to a certain decrease of promoter activity, while removal
of a sequence of approximately 220 bp containing the
CAAT box (S -400/+3) did not reduce significantly the
promoter activity. Deletion of the 5'-UTR and approxi-
mately 200 bp upstream of the transcription initiation site
(construct S -1290/-424) completely abolished promoter
activity, while the removal of only the 5'-UTR (S -400/-
206) reduced the basal transcriptional activity (Figure 3c).BMC Biology 2008, 6:31 http://www.biomedcentral.com/1741-7007/6/31
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Experiments with dicistronic vectors reveal a cryptic promoter Figure 2
Experiments with dicistronic vectors reveal a cryptic promoter. (a) The sequence under analysis was cloned in a dicis-
tronic vector between two different luciferases from Renilla and firefly. HeLa and SH-SY-5Y cells were transfected with the 
indicated constructs. Cell lysates were prepared 24 hours post-transfection and the activity of the firefly luciferase was normal-
ized to that of the Renilla luciferase. For each construct at least three independent experiments were performed. (b) The same 
sequence was cloned into a vector lacking the SV40 promoter (pRFΔP). Cell lysates were prepared 24 hours post-transfection 
and the activity of the firefly luciferase was normalized to that of the Renilla luciferase. For each construct at least three inde-
pendent experiments were performed. (c) In vitro transcribed dicistronic mRNAs were synthesized from the indicated linear-
ized constructs. HeLa cells were transfected with the capped dicistronic mRNAs and Renilla and firefly activities were 
measured 8 hours after transfection. Error bars represent standard error of the mean.BMC Biology 2008, 6:31 http://www.biomedcentral.com/1741-7007/6/31
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These experiments identified a region of 400 bp upstream
of the first ATG as a minimal promoter region active in all
cell lines tested and point to a role of the 5'-UTR to sustain
basic ubiquitous SPG4 expression.
A tissue-specific cryptic promoter in the first exon of SPG4
The promoter activity observed in the region within the
two ATGs in the experiments with the promoter-less
pRFΔP vector, as well as the role of the 5'-UTR for basal
expression, induced us to examine in detail the potential
presence of regulatory sequences in exon 1. We cloned dif-
ferent regions of the first exon of SPG4 upstream of the
firefly luciferase gene and tested their promoter activity in
all cell lines (Figure 4a). We found a strong promoter
activity in both HeLa and HEK293 cells in the region that
starts immediately downstream of the putative transcrip-
tional start site (TSS) and include both ATGs (S -207/
+259) (Figure 4b). This activity, although decreased, is
still present in constructs that contain only the coding
region (S +4/+259) or the 5'-UTR (S -207/-1). We define
the whole region between the canonical TSS, as defined in
public databases, and the AUG in position 259–261, as a
cryptic promoter. Notably, the activity of this cryptic pro-
moter appears to display some degree of cell-line specifi-
city, being highly functional in HeLa cells and HEK293
and significantly less in SH-SY-5Y cells (Figure 4b), thus
confirming our previous observations with the promoter-
less dicistronic vector.
We used the TRANSFAC program to identify binding sites
for known transcription factors in the cryptic promoter
region. This allowed us to identify two putative Sp1 bind-
ing sites that were conserved in the human and mouse
genomes (Figure 4a). Site-directed mutagenesis was
employed to insert mutations into the upstream, the
downstream, or both Sp1 sites in the construct S -207/
+259. Transfection of the mutated constructs showed a
significant reduction of the cryptic promoter activity in
HeLa cells only when both Sp1 sites are mutagenized (Fig-
ure 4c).
We previously showed that when spastin is expressed in
mammalian cells, two isoforms are produced, starting
from the first and second methionine [11]. The amount of
the shorter isoform increases when the 5'-UTR is included
in the construct [11]. In vitro transcription-translation
experiments suggested that this is largely due to alterna-
tive initiation of translation [11]. However, our novel
findings suggest that transcriptional regulation could con-
tribute to the production of the shorter isoform through
the use of the cryptic promoter. To test this possibility, we
removed the CMV promoter from a CMV-spastin-GFP
Analysis of the SPG4 minimal promoter Figure 3
Analysis of the SPG4 minimal promoter. (a) Sequence comparison using mVISTA between human and mouse genomic 
regions upstream of the first ATG of SPG4 demonstrates extensive sequence conservation. (b) Schematic representation of the 
constructs used. Different genomic sequences were cloned upstream of the firefly luciferase reporter gene. The arrow indi-
cates the transcriptional start sites of the reference SPG4 sequence. The position of a putative CAAT box is shown. (c) HeLa, 
SH-SY-5Y and HEK293 cells were cotransfected with the indicated constructs and with a CMV-Renilla luciferase plasmid. Cell 
lysates were prepared 24 hours post-transfection and the activity of the firefly luciferase was normalized to that of Renilla luci-
ferase. For each construct at least three independent experiments were performed using different DNA preparations. Error 
bars represent standard error of the mean.BMC Biology 2008, 6:31 http://www.biomedcentral.com/1741-7007/6/31
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Identification of a cryptic promoter in SPG4 exon 1 Figure 4
Identification of a cryptic promoter in SPG4 exon 1. (a) Schematic representations of the firefly luciferase reporter con-
structs used. The position of the predicted Sp1 sites is indicated. (b) HeLa, SH-SY-5Y and HEK293 cells were cotransfected 
with the indicated constructs and with a CMV-Renilla luciferase plasmid. Cell lysates were prepared 24 hours post-transfection 
and the activity of the firefly luciferase was normalized to that of Renilla luciferase. For each construct at least three independ-
ent experiments were performed using different DNA preparations. (c) Mutation of each and both predicted Sp1 sites were 
generated in the S -207/+259 construct and tested in HeLa cells as described above (n = 3). Error bars represent standard 
error of the mean. The P-value of Student's t test is shown.BMC Biology 2008, 6:31 http://www.biomedcentral.com/1741-7007/6/31
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construct and analyzed the ability of the cryptic promoter
(in this construct represented only by the region +4/+259)
to drive the expression of the short spastin isoform after
transfection in different cell lines. We found that a short
spastin-GFP isoform, with a size consistent with initiation
of translation at the second AUG, is produced in this con-
dition in Hela, HEK293 and murine spinal motoneuronal
NSC34 cells (Figure 5a and 5b and data not shown). To
confirm this data, we generated a construct containing the
GFP reporter under the control of the CMV promoter fol-
lowed by a stop codon and by the coding region of spastin
(CMV-EGFP-STOP-Spastin). Such a construct could
express spastin only if the region between the first two
ATGs functions as a promoter. Consistently, transfected
cells with high levels of GFP expression showed low levels
of spastin expression, detected with a specific antibody
(Figure 5c).
In conclusion, both reporter and expression studies with
promoter-less constructs strongly indicate that the first
SPG4 exon contains a cryptic promoter that may contrib-
ute to produce the 60-kDa isoform in several cell types in
vivo.
Two phenotype-modifier polymorphisms lie within the 
cryptic promoter
The S44L and P45Q (c.131C>T and c.134C>A) polymor-
phisms in the SPG4  gene act as phenotype-modifiers.
Patients that bear one of these polymorphisms and a
canonical  SPG4  mutation on the other allele show an
early age onset of HSP and rapid progression of symptoms
[15,16]. Since these nucleotide changes fall into the newly
identified cryptic promoter, we tested their capability to
affect the promoter activity. The polymorphisms were
inserted by mutagenesis in the constructs S -207/+259 and
S +4/+259 (Figure 6a). The activity of these mutagenized
promoters was tested in HeLa cells and compared with
wild-type constructs. The presence of the c.131C>T substi-
tution significantly diminished the activity of the pro-
moter by about a half, while no effect was detected with
the c.134C>A substitution (Figure 6b). When the substitu-
tions were inserted in the context of a larger promoter,
also containing part of the ubiquitous minimal promoter
(S -400/+259), no change in activity was observed for
either (Figure 6b).
Identification of an endogenous SPG4 transcript specific 
for the short spastin isoform
The previous experiments strongly suggest the existence of
a cryptic promoter in the first exon of the SPG4 gene. Dif-
ferentially regulated, alternative TSSs are a common fea-
ture in protein-coding genes and commonly generate
alternative N-termini [24]. Genome-wide analyses, using
short tags derived from the 5'-ends of capped RNAs
(CAGE), oligocapping methods and full-length cDNA col-
lections, can be publicly accessed in the CAGE analysis
website and in the database of transcriptional start sites
(DBTSS). We searched these databases for TSSs within the
human SPG4 gene. Remarkably, we found that both data-
bases identify an alternative promoter located within exon
1, downstream of the first ATG, defined by a clustering of
TSSs separated by fewer than 500 bp. The tags derive from
HEK293 cells, as well as from different tissues, including
brain tissue. A summary of these data is represented in
Additional file 1 and additional file 2.
To gain further experimental proof that the cryptic pro-
moter is responsible for the synthesis of a short SPG4
mRNA, we performed 5'-end RACE experiments in both
HeLa and SH-SY-5Y cells. Total RNA was isolated from the
cells. Truncated or uncapped RNA molecules were
removed by a phosphatase treatment. Subsequently, the
caps were eliminated by treatment with tobacco acid pyro-
phosphatase (TAP), and an adapter oligonucleotide was
ligated to the 5'-ends. After nested amplification with
gene-specific primers located downstream of the second
AUG, we could amplify in HeLa cells a specific product of
about 250 bp, which was absent from the minus TAP con-
trol reaction (Figure 7a). This product was cloned and
sequenced and found to initiate from nucleotide +117.
This transcript therefore, contains an ORF that starts with
AUG 259–261 and encodes the short 60-kDa spastin iso-
form. Both Sp1 sites are located upstream of the beginning
of the novel transcript, while the polymorphisms
c.131C>T and c.134C>A appear to be positioned a few
bases downstream (Figure 7b). Notably, this TSS corre-
sponds to two tags identified in HEK293 in the DBTSS
database. We could not obtain a similar 5'-end RACE
product in SH-SY-5Y cells, consistent with the lower activ-
ity of the cryptic promoter in this cell line (not shown).
Discussion
Haplo-insufficiency of spastin causes HSP, suggesting that
tight control of the protein levels is required for axonal
integrity. We previously showed that the SPG4 gene syn-
thesizes two isoforms of spastin (68 kDa and 60 kDa,
respectively), depending on the alternative initiation of
translation from two AUGs in the first exon [11]. Regula-
tion of the expression of protein isoforms simply based on
inefficient translation or leaky scanning is, however, hard
to achieve. Here, we report a transcriptional mechanism
of SPG4 regulation that may contribute to the production
of a different ratio of long and short spastin isoforms in
tissues.
We identified a ubiquitous spastin minimal promoter and
found evidence for a tissue-specific cryptic promoter in
the first exon of the gene. An evolutionary highly con-
served region of 400 bp upstream of the first in-frame
AUG of the SPG4  gene was sufficient to provide basalBMC Biology 2008, 6:31 http://www.biomedcentral.com/1741-7007/6/31
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The cryptic promoter mediates expression of the short spastin isoform in vivo Figure 5
The cryptic promoter mediates expression of the short spastin isoform in vivo. (a) HeLa cells were transfected with 
a CMV-spastin-GFP, a CMV-spastin-ΔM1 or a spastin-GFP- ΔCMV construct. Cell lysates were prepared 48 hours post-trans-
fection and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Immunoblotting for transfected spastin 
was performed with the S51 polyclonal antibody. The CMV-spastin-GFP plasmid drives expression of two spastin isoforms 
starting from the first and second methionine, as previously described [11]. Consistently, the CMV-spastin- ΔM1 construct 
produces only the shorter isoform. Notably, the promoter-less spastin construct synthesizes the short isoform, albeit at lower 
level, indicating that the cryptic promoter of spastin is active in vivo. Below each lane, the amount of transfected cell lysate 
loaded is indicated. (b) Similar results were obtained in the murine immortalized motoneuronal cell line NSC34. (c) The empty 
CMV-EGFP vector and CMV-EGFP-STOP-spastin construct were transfected in HeLa cells. Immunofluorescence was per-
formed 48 hours after transfection. Transfected cells were detected by enhanced green fluorescent protein epifluorescence, 
while spastin was revealed using the S51 polyclonal antibody. Cells expressing high levels of GFP also synthesize low levels of 
spastin. Note the different pattern of GFP (diffuse) and spastin staining (discrete, as described previously [11]).BMC Biology 2008, 6:31 http://www.biomedcentral.com/1741-7007/6/31
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The role of c.131C>T and c.134C>A polymorphisms on cryptic promoter activity Figure 6
The role of c.131C>T and c.134C>A polymorphisms on cryptic promoter activity. (a) Schematic representations of 
the firefly luciferase reporter constructs used. The position of both polymorphisms is indicated. (b) HeLa cells were trans-
fected with the indicated constructs together with a plasmid containing CMV-Renilla luciferase. Cell lysates were prepared 24 
hours post-transfection and the activity of the firefly luciferase was normalized to that of Renilla luciferase. For each construct 
at least three independent experiments were performed using different DNA preparations. Error bars represent standard 
error of the mean. The P-value of Student's t test is shown.BMC Biology 2008, 6:31 http://www.biomedcentral.com/1741-7007/6/31
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expression in HeLa, HEK293 and SH-SY-5Y cells. This
region does not contain a TATA box, but includes several
cis-acting, GC-rich elements, suggesting that the SPG4 pro-
moter belongs to the vast category of TATA-less promoters
common to mammalian housekeeping genes [25]. Inclu-
sion in the reporter constructs of upstream genomic
regions did not significantly increase transcriptional activ-
ity. Furthermore, deletion of a putative CAAT box, not
conserved in the mouse, did not decrease substantially
promoter activity. In contrast, a certain drop in activity
was found when the majority of the 5'-UTR of the gene
was removed from all the constructs tested. A possible
explanation is that the 5'-UTR itself may contain addi-
tional TSS or regulatory elements that cooperate with
upstream sequences to allow basal transcription of the
SPG4 gene. Consistently high levels of sequence conserva-
tion are observed in the 5'-UTR among different species
from human to chicken.
The latter hypothesis is supported by the finding of a cryp-
tic promoter in the first exon of the SPG4 gene. The region
between the most upstream TSS (corresponding to posi-
tion -221) and the first ATG, and the region between the
first and the second in-frame ATGs, both, alone and even
stronger in combination, are able to drive the expression
of a reporter gene in promoter-less vectors. Collectively,
we define these regions in SPG4 exon 1 as a cryptic pro-
moter. Furthermore, promoter-less constructs containing
only the coding sequence of spastin drove the expression
of the shorter spastin isoform in Hela, HEK293 and
NSC34 cells. These are murine immortalized spinal
motoneurons that express both long and short spastin iso-
forms [11]. This result suggests that the cryptic promoter
may also be active in neurons implicated in human
pathology. Remarkably, the cryptic promoter shows some
degree of tissue-specificity, as shown by low activity in the
neuroblastoma-derived SH-SY-5Y cells.
The presence of shorter capped SPG4 mRNAs is supported
by the successful identification of a novel SPG4 transcript
that starts downstream of the first AUG in HeLa cells by 5'-
end RACE experiments. Moreover, our experimental data
are consistent with high-throughput, genome-wide stud-
ies, which identified a cluster of TSSs within both the
human and murine SPG4 genes located in close proximity
to the TSS of the novel transcript identified in our study.
The previous results strongly suggest that the SPG4 gene
has multiple core promoters containing multiple TSSs, the
use of which generates diversity, not only in the tran-
scripts, but most importantly, in the proteins produced. A
similar scenario is emerging with more and more fre-
quency from studies of mammalian core promoters [25].
As expected for a broad promoter with multiple TSSs, sev-
eral CpG islands boxes and multiple binding sites for the
An endogenous SPG4 transcript specific for the 60-kDa spastin isoform Figure 7
An endogenous SPG4 transcript specific for the 60-kDa spastin isoform. (a) 5'-end RACE performed on total RNA 
extracted from HeLa cells detects a specific product of about 250 base pairs that is lacking in the minus tobacco acid pyrophos-
phatase control sample. (b) Sequence of the SPG4 first exon starting from the transcriptional start site as defined in public data-
bases and ending with the second ATG in position 259–261. Sp1 sites are underlined, the position of the c.131C>T and 
c.134C>A polymorphisms and the two in-frame ATGs are shown in bold, while arrows indicate the traditional and novel tran-
scriptional start site found in this study.BMC Biology 2008, 6:31 http://www.biomedcentral.com/1741-7007/6/31
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transcription factor Sp1  are present in the cryptic pro-
moter. It has been suggested that Sp1 may direct the basal
machinery to form a pre-initiation complex within a
loosely defined window [26]. Mutagenesis of two evolu-
tionary conserved Sp1 sites decreased the activity of the
cryptic promoter, suggesting that Sp1 or Sp family mem-
ber transcription factors may bind to the cryptic promoter.
Sp1  elements are required for the expression of many
ubiquitous, tissue-specific and viral genes [27]. Interest-
ingly, Sp1 levels decrease with cellular aging [28]. Further
studies however, are required to define the transcription
factors involved in SPG4 expression.
Western blot analysis strongly indicates that the 60-kDa
spastin isoform is predominant in many tissues and cells
[11,12]. Based on our data, we propose that a combina-
tion of transcriptional and translational mechanisms is
employed in concert to modulate the levels of spastin iso-
forms in cells. At the transcriptional level, cells may syn-
thesize the 60-kDa isoform simply through the
production of a shorter transcript that possesses as first in-
frame AUG, the one in position 259–261. However, an
additional mechanism to ensure preferential synthesis of
the 60-kDa spastin isoform likely arises during transla-
tion, due to several constraints imposed on translation
from the first in-frame AUG, such as the presence of a 73%
GC-rich 5'-UTR, an overlapping uORF and a poor Kozak's
context [19]. Indeed, in our experiments with spastin
expression constructs, it is clear that the short spastin iso-
form is expressed at high levels when the SPG4 coding
sequence is under the control of the CMV promoter, sug-
gesting that translation of this isoform occurs even when
the synthesis of a longer mRNA is favored.
Our study tends to exclude a role for a cap-independent
mechanism through recognition of an IRES in the transla-
tion of the spastin 60-kDa short isoform. This latter mech-
anism has been extensively demonstrated in viral
transcripts, and more recently has also been found in a
number of eukaryotic transcripts, whose translation needs
to occur also in circumstances in which cap-dependent
translation is inhibited. Functional IRES elements have
been proposed in several eukaryotic genes, but subse-
quent studies using more sensitive procedures have ques-
tioned the validity of several of them [29-31]. Similarly,
we showed by direct RNA transfection of a dicistronic
transcript that the predicted IRES in the SPG4 exon 1 is not
functional, further confirming the imprecision of bioin-
formatic approaches to predict IRES sequences and stress-
ing the importance of adequate functional validation.
It remains to be established why several mechanisms have
evolved to maintain the low levels of the long 68-kDa
spastin isoform in most cells and tissues. This apparently
seems to contrast with the evolutionary conservation of
the first AUG and even of the uORF in several organisms,
and may point to the need for a regulated expression of
this isoform, or a possible toxic effect if expressed at a high
level.
The identification of the cryptic SPG4  promoter and a
shorter SPG4 transcript may have implications in human
pathology. We found that a previously reported polymor-
phism (c.131C>T) that acts as a disease modifier falls into
the cryptic promoter region and decreases its activity sig-
nificantly. Notably, this polymorphism is a few base pairs
downstream of the TSS of the novel transcript described
here and therefore, within a bona fide SPG4 core pro-
moter. However, a second polymorphism, c.134C>A, did
not affect cryptic promoter activity, casting doubts on
whether these polymorphisms actually act transcription-
ally. Further studies on cell lines derived from HSP fami-
lies in which both a mutant SPG4  allele and the
polymorphism segregate are needed to address this issue.
Conclusion
Our study describes alternative promoter usage and heter-
ogeneity of transcription initiation for the SPG4 gene. A
canonical promoter has features typical of housekeeping
genes, while a cryptic promoter in the 5'-UTR and coding
region of spastin seems to provide tissue-specificity. Use
of these alternative promoters generates SPG4  mRNAs
with 5'-UTRs of different length and with different AUGs
driving the production of different spastin isoforms. Our
study emphasizes the need to take into account SPG4
complex transcriptional regulation to achieve a better
understanding of the biology of spastin and the patho-
genic effect of mutations or polymorphisms located in the
first exon of the gene.
Methods
Constructs
In all numeric references in this study, nucleotide +1 cor-
responds to the A of the first ATG codon according to den
Dunnen and Antonarakis [32].
Dicistronic constructs (pRF)
The +4/+258 region of SPG4 was amplified by polymerase
chain reaction (PCR) from human genomic DNA using
Pfu Ultra (Stratagene) and cloned SpeI/NcoI into pRF and
pRFΔP (Fw: 5'-GCAGTACTTAATTCTCCGGGTGGACGA-
3', Rev: 5'-ATCCATGGGAGGGCGCGGGAGAAGCG-3',
SpeI and NcoI sites in bold, respectively). Both dicistronic
vectors were a kind gift from Dr J-T Zhang [30]. For RNA
transfection experiments, the dicistronic cassette was
excised from pRF +4/+258 using a BamHI/NheI digestion
and then cloned BamHI/EcoRV into the multiple cloning
site of pBluescript KS (Stratagene).BMC Biology 2008, 6:31 http://www.biomedcentral.com/1741-7007/6/31
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Spastin promoter constructs (S)
All of these constructs were obtained by cloning different
portions of the human genomic sequence upstream of the
SPG4 start codon into the pGL3 vector (Promega). The S -
1290/-1 insert was amplified by PCR using Pfu Ultra
(Stratagene) from human genomic DNA and cloned in
the XhoI/HindIII sites of pGL3 vector (Fw: 5'-ATCTCGA-
GAACCCAGCAGCTCTGGGGGA-3', Rev: 5'-ATAAGCTT-
TCACAGCTCTCACTGCCGCC-3', XhoI and HindIII sites
in bold, respectively). S -621/-1 was obtained from S -
1290/-1 by SmaI/EcoRV excision and self-ligation. S -207/
-1 was obtained from S -1290/-1 by KpnI/PstI excision and
self-ligation. S -1290/-424 was obtained from S -1290/-1
by HindIII/PstI excision and self-ligation. The S -400/+259
insert was amplified by PCR using Pfu Ultra (Stratagene)
from human genomic DNA and cloned XhoI/HindIII (Fw:
5'-ATCTCGAGTGGGAACTGTAGTTGAGT-3', Rev: 5'-
ATAAGCTTCGGAGCTCCTCCTGGCTG-3', XhoI and Hin-
dIII sites in bold, respectively). S -207/+259 was obtained
from S -400/+259 by SmaI/PstI excision and self-ligation.
S +4/+259 was obtained from S -400/+259 by SmaI/EcoRI
excision and self-ligation. S -400/+3 was obtained from S
-400/+259 by EcoRI/HindIII excision and self-ligation. S -
400/-206 was obtained from S -400/+259 by PstI/HindIII
excision and self-ligation.
Expression constructs
Spastin-GFP-ΔCMV was obtained from CMV-spastin-GFP
vector [3] by digestion with NruI/KpnI and self-ligation.
Spastin-GFP-ΔM1 was obtained from spastin-GFP vector
by digestion with EcoRI/KpnI and self-ligation. To obtain
the CMV-EGFP-STOP-spastin construct, the SPG4 coding
region was cloned blunt in the NotI site of pEGFP N°2
(Clontech).
Site-directed mutagenesis
Site-directed mutagenesis was performed by PCR reac-
tions using Pfu Ultra (Stratagene). After amplification, 10
U of DpnI were added to the PCR product and incubated
for 1 hour at 37°C. The mutagenized DNA was trans-
formed into E. coli XL1Blue super-competent cells. The
c.131C>T polymorphism was introduced into S -400/
+259, S -207/+259 and S +4/+259 vectors using the fol-
lowing set of oligos: Fw: 5'-GCCCCTCCGCCCGAGTT-
GCCGCATAAGCGGAAC-3', Rev: 5'-
GTTCCGCTTATGCGGCAACTCGGGCGGAGGGGC-3'
(mismatches reported in bold). The c.134C>A polymor-
phism was introduced into S -400/+259, S -207/+259 and
S +4/+259 vectors using the following set of oligos: Fw: 5'-
CCTCCGCCCGAGTCGCAGCATAAGCGGAACCTG-3',
Rev: 5'-CAGGTTCCGCTTATGCTGCGACTCGGGCG-
GAGG-3' (mismatches reported in bold). Mutagenesis of
Sp1 sites was introduced in the S-207/+259 construct. The
upstream Sp1 site was mutated using this set of oligos: Fw:
5'-AGGAAGGAGAAAGGGGAAGGGCAAGCG-
GGCAGCGTGCGG-3', Rev: 5'-CCGCACGCT-
GCCCGCTTGCCCTTCCCCTTTCTCCTTCCT-3'
(mismatches reported in bold). The downstream Sp1 site
was mutated using the following set of oligos: Fw: 5'-
CCCTTGCCTGGCCCCAACCCCAACCGCCGCCG-
GGCCGGC-3', Rev: 5'-GCCGGCCCGGCGGCGGTT-
GGGGTTGGGGCCAGGCAAGGG-3' (mismatches
reported in bold). All mutagenized vectors were control-
led by DNA sequencing.
DNA sequencing
DNA sequencing was performed by using a 3100 Genetic
Analyzer (Applied Biosystems) and BigDye Terminator
v1.1 Cycle Sequencing kit (Applied Biosystems) according
to the manufacturer's specifications.
Luciferase assays
Renilla (RL) and firefly luciferase (FL) activities were meas-
ured using the Dual-Luciferase Reporter System
(Promega) and a Victor2 1420 Multilabel Counter (Perkin
Elmer). At 24 hours post-transfection, 20 μl of cell lysate
was combined sequentially with FL- and RL-specific sub-
strates according to the protocol supplied by the manufac-
turer. Light emission was measured 2 seconds after
addition of each of the substrates and integrated over a
10-second interval. All experiments were performed in
duplicates and were repeated at least three times using dif-
ferent DNA preparations.
In vitro transcription
pRF and pBS-pRF +4/+258 plasmids were linearized prior
to transcription by BamHI restriction, purified by incuba-
tion at 50°C for 30 minutes with 10 μg proteinase K and
0.5% sodium dodecyl sulfate (SDS), and precipitated with
25 mM ethylene diamine tetraacetic acid (EDTA) and 300
mM sodium acetate pH 5.2. Capped RNA transcripts were
synthesized by using MAXIscript in vitro transcription kit
(Ambion) according to the manufacturer's specifications.
Briefly, recombinant T7 or T3 polymerases were used to
synthesize mRNA from 2.5 μg linearized DNA and 0.5
mM Ribo m7 G Cap Analog (Promega) was added to the
reaction mix. In vitro transcription was performed by incu-
bation at 37°C for 1 hour in 40 U of RNAsin RNAse inhib-
itor (Promega). Following transcription, reactions were
treated with DNAse I for 15 minutes at 37°C.
Cell culture, DNA and mRNA transfection and 
immunofluorescence
HeLa, HEK293 and NSC34 cells were cultured in Dul-
becco's Modified Eagle's Media (Euroclone) supple-
mented with 10% or 5% fetal bovine serum, 200 U/ml
penicillin, 200 μg/ml streptomycin and 2 mM glutamine.
SH-SY-5Y cells were cultured in Minimum Essential Media
(Euroclone) supplemented with 10% Fetalclone III
(Hyclone), 200 U/ml penicillin, 200 μg/ml streptomycinBMC Biology 2008, 6:31 http://www.biomedcentral.com/1741-7007/6/31
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and 2 mM glutamine. All cultures were grown as a monol-
ayer in a humidified incubator at 37°C in an atmosphere
of 5% CO2.
Transient DNA transfections were performed by using
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer's specifications. Briefly, 8 × 104 cells per well of a
24-well plate were seeded the day prior to transfection.
Cells were transfected with DNA (500 ng) and cultured for
an additional 24 or 48 hours. In cotransfection experi-
ments, pRL-CMV DNA was added in 1:100 ratio.
mRNA transfections were performed by using Transmes-
senger Transfection Reagent (Qiagen) according to the
manufacturer's specifications. Briefly, 8 × 104 cells per well
of a 24-well plate were seeded the day prior to transfec-
tion. Cells were transfected with mRNA (2 μg) and cul-
tured for an additional 8 hours.
Immunofluorescences were performed as described previ-
ously [3].
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
and immunoblotting
Cells were scraped in phosphate-buffered saline and lysed
for 30 minutes in RIPA buffer (50 mM Tris-HCl, 1% NP-
40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA,
pH 7.4) and protease inhibitor cocktail (Sigma-Aldrich)
in ice. Protein samples were resuspended in SDS sample
buffer and subjected to standard sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) followed
by protein transfer to a polyvinylidene difluoride mem-
brane (Amersham). Spastin was revealed by immunoblot-
ting with S51 polyclonal antibody [7].
5'-end RACE
Total RNA was extracted from cells using TRIzol (Invitro-
gen) according to the manufacturer's specifications. Rapid
amplification of 5'-ends cDNA was carried out using a
FirstChoice RLM-RACE kit (Ambion) according to the
manufacturer's instructions with the following excep-
tions. The outer PCR reaction was carried out with 10
pmol gene-specific outer primer (5'-ACCATTC-
CACAGCTTGCTCCTTCT-3'), 1.25 units of Pfu  Ultra
(Stratagene) and 1.5 ng first-strand cDNA reaction. The
PCR conditions were as follows: (1×) 94°C, 3 minutes;
(35×) 94°C, 30 seconds; 55°C, 30 seconds; 72°C, 90 sec-
onds; (1×) 72°C, 10 minutes. The inner PCR reaction was
carried out with 10 pmol gene-specific inner primer (5'-
CGCAAGCTTAGGCCTGTTTGTGGAAGACTCGGACG-3',
BamHI site in bold), using the same conditions as for the
outer PCR. PCR products were separated on 2% agarose
gel, cloned BamHI into a pBluescript KS-vector (Strata-
gene) and sequenced.
Bioinformatics analysis
Conservation studies were performed using the human
BLAT search database [33]. Alignments between human
and mouse sequences were performed by using mVISTA
[34] with the following parameters: min_Y (minimum Y
value on the mVISTA plot) 40%, min_id (minimum con-
servation identity) 50%, min_length (minimum length
for a CNS) 50 bp. IRES prediction was performed by using
UTRScan [35]. Transcription factors binding sites were
predicted using two different matrixes. MATCH™ [36]
parameters: profile, vertebrates; cut-off selection, mini-
mize the sum of both error rates. PATCH™ [36] parame-
ters: sites selection, vertebrate sites; minimum length of
site, 10 bp; maximum number of mismatches, 0; mis-
match penalty, 100; lower score boundary, 87.5. Bio-
informatic analysis of 5'-end full-length SPG4 cDNas was
performed using the CAGE analysis website [37] and the
DBTSS [38].
Statistical analysis
Data are expressed as the mean ± standard error of the
mean. Statistical analysis was performed using a two-way
unpaired Student's t test.
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